Clinical trial · Observational
Non-interventional Study With Pomalidomide (Imnovid®)
Non-interventional Study of Pomalidomide (Imnovid®) in Combination With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT02075996CI-TRIAL-00060310PoseidoncompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this non-interventional study is to collect data on the efficiency and safety of pomalidomide in combination with dexamethasone in the routine application
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Pomalidomide following lenalidomide
- description
- 75 patients with pomalidomide directly following lenalidomide treatment
- label
- Pomalidomide following other therapy
- description
- 75 patients with pomalidomide following any other prior therapy. This includes lenalidomide in earlier lines than the most recent line.
Primary outcomes (1)
- measure
- Progression free survival (PFS)
- timeFrame
- 6 years
Secondary outcomes (9)
- measure
- Overall Response Rate (ORR)
- timeFrame
- 6 years
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with relapsed or refractory multiple myeloma Patients must have received at least two prior lines of treatment (induction therapy followed by stem cell transplantation ± maintenance therapy is considered one prior therapy) and must have progressed under the most recent therapy regimen * Adult male and female patients (at least 18 years with no upper age limit) * Written informed consent to data collection and pseudonymized data transfer * The conditions of the Pregnancy Prevention Programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential (see summary of product characteristics Imnovid®) * Other criteria according to summary of product characteristics Imnovid® Exclusion Criteria: * Missing patient's informed consent * Pregnant or breast-feeding women * Male patients, not capable of complying the required preventive measures (see summary of product characteristics Imnovid®) * Other criteria according to summary of product characteristics Imnovid®
References
Publications (1)
- DERIVEDDechow T, Aldaoud A, Behlendorf T, Knauf W, Eschenburg H, Groschek M, Hansen R, Soling U, Grebhardt S, Siebenbach HU, Vannier C, Potthoff K. Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials. Eur J Haematol. 2022 Feb;108(2):133-144. doi: 10.1111/ejh.13719. Epub 2021 Nov 15. PMID 34714555